Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcturus Therapeutics HoldingsARCT -4.32%48 Median PS Value is $3.02 as of Aug. 10, 2026, which is 172% above its 10-year median of 1.11. GuruFocus rates ARCT with a GF Score™ of 48/100 and a GF Value™ of $2.19 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 278 Biotechnology companies, Arcturus Therapeutics Holdings ranks worse than 90.65% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Arcturus Therapeutics Holdings's Median PS Value or its related term are showing as below:
ARCT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53 Med: 1.11 Max: 2.51
Current: 2.35
During the past 13 years, the highest Price to Median PS Value of Arcturus Therapeutics Holdings was 2.51. The lowest was 0.53. And the median was 1.11.
ARCT's Price-to-Median-PS-Value is ranked worse than 90.65% of 278
companies
in the Biotechnology industry
Industry Median: 0.625
vs ARCT: 2.35
Arcturus Therapeutics Holdings (NAS:ARCT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Arcturus Therapeutics Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
7.09
/
3.02
=
2.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Median PS Value Related Terms
Arcturus Therapeutics Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Median PS Value Chart
ARCT vs EQ, SMNR, TNXP: Median PS Value Comparison
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.4217.
Arcturus Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.683.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a Median PS Value of $3.02 as of Aug. 10, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Arcturus Therapeutics Holdings and its competitors. This is 172% above median its historical median of 1.11. Over the past decade, Arcturus Therapeutics Holdings' Median PS Value has ranged from 0.53 to 2.51. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #252 out of 278 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Arcturus Therapeutics Holdings' Median PS Value too high?
Arcturus Therapeutics Holdings' current Median PS Value of $3.02 is 172% above median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 2.51. The Biotechnology industry median Median PS Value is 0.63. Arcturus Therapeutics Holdings' value of $3.02 is 383.2% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #252 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Median PS Value compare to EQ and SMNR?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #252 out of 278 companies for Median PS Value. This places Arcturus Therapeutics Holdings in the lower half of its industry. The industry median Median PS Value is 0.63. Arcturus Therapeutics Holdings' value of $3.02 is 383.2% above this benchmark. Historically, Arcturus Therapeutics Holdings' own Median PS Value has ranged from 0.53 to 2.51 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 0.63, Arcturus Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Median PS Value of $3.02 is 383.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Median PS Value is $3.02, which is 172% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.19, compared to a current price of $7.09 — trading 223.7% above its estimated fair value. The current Median PS Value is $3.02, which is 172% above median its 10-year median of 1.11 and 383.2% above the Biotechnology industry median of 0.63. Arcturus Therapeutics Holdings' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Median PS Value is $3.02 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $7.09 is trading 223.7% above its estimated GF Value™ of $2.19.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
Median PS Value: $3.02 (172% above median its 10-year median of 1.11)
GF Value™: $2.19 vs. price of $7.09 (223.7% above fair value)
Industry Position: 383.2% above the Biotechnology median (#252 of 278)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
48GF Score
Get the complete analysis for ARCT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
